(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 August 2020 (13.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/163730 A2

(51) International Patent Classification:
A61K 39/00 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/US2020/017235

(22) International Filing Date:
07 February 2020 (07.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/802,870 08 February 2019 (08.02.2019) US

(71) Applicants: **AC IMMUNE S.A.** [CH/CH]; EPFL Innovation Park, Building B, CH-1015 Lausanne (CH). **JANSSEN PHARMACEUTICALS, INC.** [US/US]; 1125 Trenton-Harbourton Rd., Titusville, NJ 08560 (US).

(72) Inventors: **PFEIFER, Andrea**; EPFL Innovation Park, Building B, CH-1015 Lausanne (CH). **MUHS, Andreas**; EPFL Innovation Park, Building B, CH-1015 Lausanne (CH). **PIHLGREN BOSCH, Maria**; EPFL Innovation Park, Building B, CH-1015 Lausanne (CH). **VUKICEVIC VERHILLE, Marija**; EPFL Innovation Park, Building B, CH-1015 Lausanne (CH). **PIOT, Nicolas**; EPFL Innovation Park, Building B, CH-1015 Lausanne (CH). **GHIMIRE, Saroj Raj**; EPFL Innovation Park, Building B, CH-1015 Lausanne (CH). **RAMSBURG, Elizabeth Anne**; 1125 Trenton-Harbourton Rd., Titusville, NJ 08560 (US). **DE MARCO, Donata**; 1125 Trenton-Harbourton Rd., Titusville, NJ 08560 (US). **SADAKA, Charlotte**; 1125 Trenton-Harbourton Rd., Titusville, NJ 08560 (US).


(74) Agent: **SIMS, Sara E.** et al.; ICE MILLER LLP, 1735 Market Street, Suite 3450, Philadelphia, PA 19103-7509 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

(54) Title: METHOD OF SAFE ADMINISTRATION OF PHOSPHORYLATED TAU PEPTIDE VACCINE

Fig. 1



(57) Abstract: Methods for inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in humans are described. The methods include administering to the subject an effective amount of liposomes including a toll-like receptor 4 agonist and a Tau phosphopeptide presented on the surface of the liposome.

WO 2020/163730 A2

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*